Ilke Aernout

Challenges and opportunities in mRNA vaccine development against bacteria

Ilke Aernout (UGent) , Rein Verbeke (UGent) , Fabien Henri Thery (UGent) , Patrick Willems (UGent) , Uri Elia, Stefaan De Smedt (UGent) , Rino Rappuoli, Dan Peer, Francis Impens (UGent) and Ine Lentacker (UGent)

(2025) NATURE MICROBIOLOGY. 10(8). p.1816-1828

Add to list

Journal Article
A1
open access

Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation

Arthur Esprit, Dorien Autaers, Ilke Aernout (UGent) , Ine Lentacker (UGent) , Steve Pascolo, Kris Thielemans, Karine Breckpot and Lorenzo Franceschini

(2025) MOLECULAR THERAPY NUCLEIC ACIDS. 36(3).

Add to list

Journal Article
A1
open access

Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

Sofie Meulewaeter (UGent) , Margo De Velder (UGent) , Diethard Reckelbus (UGent) , Kevin Mwangi (UGent) , Thomas Ehouarne (UGent) , Ilke Aernout (UGent) , Yanou Engelen (UGent) , Fëllanza Halimi (UGent) , Isis Van herteryck (UGent) , Lobke De Bels (UGent) , et al.

(2025) MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 33(2).

Add to list

Book Chapter

Current state of mRNA vaccine development against Mycobacterium tuberculosis

Ilke Aernout (UGent) , Rein Verbeke (UGent) , Stefaan De Smedt (UGent) , Francis Impens (UGent) and Ine Lentacker (UGent)

(2025) Trends in mRNA vaccine research. p.325-335

Add to list

Journal Article
A1
open access

Photoporation of NK-92MI cells with biodegradable polydopamine nanosensitizers as a promising strategy for the generation of engineered NK cell therapies

Charlotte Hinnekens (UGent) , Aranit Harizaj (UGent) , Dominika Berdecka, Ilke Aernout (UGent) , Molood Shariati (UGent) , Stefanie Peeters, Eva Lion, Stefaan De Smedt (UGent) , Bart Vandekerckhove (UGent) , Kevin Braeckmans (UGent) , et al.

(2024) APPLIED MATERIALS TODAY. 40.

Add to list

Journal Article
A1
open access

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

Sigrid D’haese, Sabine den Roover, Rein Verbeke (UGent) , Ilke Aernout (UGent) , Sofie Meulewater, Joëlle Cosyns, Jessy Meert, Sarah Vanbellingen, Thessa Laeremans, Ine Lentacker (UGent) , et al.

(2024) MOLECULAR THERAPY NUCLEIC ACIDS. 35(4).

Add to list

Journal Article
A1
open access

Immunopeptidomics mapping of Listeria monocytogenes T cell epitopes in mice

Adillah Gul (UGent) , Lecia L. Pewe, Patrick Willems (UGent) , Rupert Mayer (UGent) , Fabien Henri Thery (UGent) , Caroline Asselman (UGent) , Ilke Aernout (UGent) , Rein Verbeke (UGent) , Denzel Eggermont (UGent) , Laura Van Moortel (UGent) , et al.

(2024) MOLECULAR & CELLULAR PROTEOMICS. 23(9).

Add to list

Journal Article
A1
open access

Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria

Sofie Meulewaeter (UGent) , Ilke Aernout (UGent) , Joke Deprez (UGent) , Yanou Engelen (UGent) , Margo De Velder (UGent) , Lorenzo Franceschini, Karine Breckpot, Serge Van Calenbergh (UGent) , Caroline Asselman (UGent) , Katie Boucher (UGent) , et al.

(2024) JOURNAL OF CONTROLLED RELEASE. 370. p.379-391

Add to list

Journal Article
A1
open access

Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium

Joke Deprez (UGent) , Rein Verbeke (UGent) , Sofie Meulewaeter (UGent) , Ilke Aernout (UGent) , Heleen Dewitte (UGent) , Tine Decruy (UGent) , Julie Coudenys (UGent) , Julie Van Duyse (UGent) , Gert Van Isterdael (UGent) , Dan Peer, et al.

(2023) NATURE NANOTECHNOLOGY. 18. p.1341-1350

Add to list

Journal Article
A1
open access

Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes

Rupert Mayer (UGent) , Rein Verbeke (UGent) , Caroline Asselman (UGent) , Ilke Aernout (UGent) , Adillah Gul (UGent) , Denzel Eggermont (UGent) , Katie Boucher (UGent) , Fabien Henri Thery (UGent) , Teresa Maia (UGent) , Hans Demol (UGent) , et al.

(2022) NATURE COMMUNICATIONS. 13(1).

Academic Bibliography

Ilke Aernout

Challenges and opportunities in mRNA vaccine development against bacteria

Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation

Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

Current state of mRNA vaccine development against Mycobacterium tuberculosis

Photoporation of NK-92MI cells with biodegradable polydopamine nanosensitizers as a promising strategy for the generation of engineered NK cell therapies

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

Immunopeptidomics mapping of Listeria monocytogenes T cell epitopes in mice

Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria

Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium

Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes

Contents

Support

Contact